NCT06700356 Thalamus Seizure Detection With a Deep Brain Stimulator System
| NCT ID | NCT06700356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Epilepsy; Seizure |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2026-06-01 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the inclusion criteria to participate in this study: * 18 years of age and older. * Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS). * Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study. Exclusion Criteria: All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation: * Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization. * Women will verify not pregnant, and if applicable, have urine pregnancy test. * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Contact & Investigator
Nicholas Gregg
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06700356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy; Seizure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06700356 currently recruiting?
Yes, NCT06700356 is actively recruiting participants. Contact the research team at crockett.karla@mayo.edu for enrollment information.
Where is the NCT06700356 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06700356 clinical trial?
NCT06700356 is sponsored by Mayo Clinic. The principal investigator is Nicholas Gregg at Mayo Clinic. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.